VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer

Genitourinary Cancers MORE >>

A new formulation of abiraterone acetate in combination with methylprednisolone has been approved by the FDA as a treatment for men with metastatic castration-resistant prostate cancer, according to Sun Pharma, the company commercializing the treatment.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.